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Endocardial and Epicardial Derived FGF Signals
Regulate Myocardial Proliferation
and Differentiation In Vivo
as the major functional FGF in the developing and adult
myocardium. Despite a wealth of in vitro data demon-
strating that established cardiomyoblasts proliferate in
response to various FGFs (including FGF2), there is a
paucity of data that actually links FGF signaling to myo-
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Washington University Medical School cardial growth and development in vivo. Fgf2/ mice
develop normally and have normal cardiac structure andSt. Louis, Missouri 63110
2 Institute of Biotechnology mass. However, Fgf2/ adults display a mild cardiovas-
cular phenotype, resulting in decreased vascular toneUniversity of Helsinki
Helsinki FIN-00014 and an impaired hypertrophic response to pressure
overload (Schultz et al., 1999; Zhou et al., 1998). TheseFinland
data, although not informative with respect to cardiac
development, suggest that FGF2 signaling is important
for the maintenance of cardiac physiology in the adult.Summary
There exist at least 22 members of the FGF family.
By sequence similarity, these 22 FGFs can be subdi-The epicardium regulates growth and survival of the
underlying myocardium. This activity depends on in- vided into evolutionarily conserved subgroups (Itoh and
Ornitz, 2004). FGFswithin agiven subgroupare known totrinsic retinoic acid (RA) and erythropoietin signals.
However, these signals do not act directly on themyo- possess similar receptor specificity (Ornitz et al., 1996).
Four distinct FGFR tyrosine kinases bind and are acti-cardium and instead are proposed to regulate the pro-
duction of an unidentified soluble epicardial derived vated bymost FGFs. AlternativemRNA splicing of Fgfr1,
Fgfr2, and Fgfr3 produces FGFRs with unique ligandmitogen. Here, we show that Fgf9, Fgf16, and Fgf20
are expressed in the endocardium and epicardium and binding properties. Splicing tends to be tissue-specific,
producing epithelial variants (b splice forms) andmesen-that RA can induce epicardial expression of Fgf9. Us-
ing knockout mice and an embryonic heart organ cul- chymal variants (c splice forms) (Ornitz and Itoh, 2001).
Following ligand binding and receptor dimerization, au-ture system, we show that endocardial and epicardial
derived FGF signals regulate myocardial proliferation tophosphorylation activates the FGFR and allows it to
bind and phosphorylate intracellular signaling mole-during midgestation heart development. We further
show that this FGF signal is received by both FGF cules. FGFR signals are transduced by the ras-raf-map
kinase pathway and the phospholipase C- (PLC-)receptors 1 and 2 acting redundantly in the cardiomy-
oblast. In the absence of this signal, premature differ- pathway (Szebenyi and Fallon, 1999).
The disparity between the potent activity of FGFs onentiation results in cellular hypertrophy and newborn
mice develop a dilated cardiomyopathy. FGFs thus cardiomyoblasts in culture and the lack of in vivo data
functionally linking FGFs to cardiovascular developmentconstitute all or part of the epicardial signal regulating
myocardial growth and differentiation. has yet to be resolved. Here, we demonstrate specific
expression of Fgf9, Fgf16, and Fgf20 in the epicardium
and endocardium of the midgestation mouse heart. WeIntroduction
present evidence that epicardial and endocardial FGF
signaling is essential for myocardial proliferation and dif-Cardiac development begins with the specification of
the cardiac fate (cardiogenesis) and subsequent forma- ferentiation invivo, acting redundantly throughFGFR1 and
FGFR2. The ability of retinoic acid to induce the expres-tion of the linear heart tube. The linear heart tube under-
goes rightward looping to establish the future positions sion of Fgf9 in epicardial cells and heart explants sug-
gests that FGFs may comprise all or part of the elusiveof the atria, ventricle, and outflow tract (future aorta and
pulmonary artery). Following looping, the cardiomyo- epicardial to myocardial signal.
blast population undergoes a robust expansion resulting
in marked growth of the embryonic heart. This growth Results
is proposed to be regulated by the epicardium, a popula-
tion of mesothelial- and possibly neural crest-derived FGF9 Is a Retinoic Acid Inducible Factor Expressed
cells overlying the myocardium that later gives rise to in the Epicardium and Endocardium
the coronary vasculature and interstitial cells of themyo- Epicardial signals are proposed to be key regulators
cardium (Dettman et al., 1998; Mikawa and Gourdie, of cardiomyoblast proliferation. Retinoic acid (RA) and
1996; Stottmann et al., 2004). erythropoetin (Epo) have been shown to regulate the
During this rapid growth stage, the only fibroblast expression of such epicardial mitogens (Chen et al.,
growth factors (Fgfs) and Fgf receptors (Fgfrs) known 1998, 2002; Stuckmann et al., 2003; Wu et al., 1999).
to be expressed in the mouse and chick ventricles are Since several Fgfs (including Fgf9) are expressed during
Fgf2, Fgf9, and Fgfr1 (Colvin et al., 1999; Pennisi et al., cardiac development and FGF activity is mitogenic for
2003). Many studies to date implicate FGF2 (basic FGF) cultured cardiomyoblasts (Engelmann et al., 1993; Pasu-
marthi et al., 1996; Speir et al., 1992), we suspected that
FGF(s) might be one of the RA and/or Epo inducible*Correspondence: dornitz@molecool.wustl.edu
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and bulboventricular groove (Figures 1E and 1F). E12.5
hearts showed significantly stronger expression of Fgf9
in the lateral regions of both the right and left ventricles
and most intense expression at the apex of the right
ventricle proximal to the interventricular groove (Figures
1H and 1I). Sections through both E10.5 and E12.5 Fgf9-
stained hearts revealed that Fgf9 is expressed specifi-
cally in endocardial cells lining the myocardial wall and
trabeculae (Figures 1G and 1J). At E10.5, Fgf9 was also
prominently expressed in the epicardium (Figure 1G).
Ventricular Hypoplasia in Fgf9/ Embryos
SinceFgf9 is expressed in the epicardiumandRAsignal-
ing regulates Fgf9 expression in epicardial cells, we hy-
pothesized that FGF9 may constitute one of the pro-
posed epicardial derived mitogens induced by RA
signaling. To determine whether FGF9 is an important
mitogen for cardiomyoblasts in vivo, we examined
Fgf9/ mice. Fgf9/ mice die at birth with hypoplastic
lungs and an enlarged dilated heart (Colvin et al., 2001).
Further examination revealed that beginning at embry-
onic day 12.5 (E12.5), Fgf9/ hearts were smaller com-
pared to wild-type littermates. Moreover, Fgf9/ hearts
showed a disproportionate loss of tissue at the apex of
the heart and in regions surrounding the interventricular
groove, consistent with the presented and previously
published expression patterns of Fgf9 (Colvin et al.,
1999). By E13.5, these changes become increasingly
apparent (Figures 2A and 2B).
FGFs are known to promote both mitogenic activityFigure 1. FGF9 Is a Retinoic Acid Inducible Factor and Is Expressed
and cell survival (Ornitz and Itoh, 2001). To determineduring Embryonic Heart Development
whether the aforementioned tissue loss was a result(A–C) In situ hybridization demonstrating that Fgf9 expression is
of decreased cell proliferation, increased cell death, orupregulated in heart organ culture by RA (B) but not Epo (C) treat-
ment compared to control hearts (A). both, E12.5 wild-type and Fgf9/ hearts were labeled
(D) qRT-PCR analysis showing that Fgf9 expression is upregulated with BrdU and assayed for markers of cell death. Exami-
by RA but not by Epo treatment in cultured primary epicardial cells. nation of BrdU-labeled tissue demonstrated decreased
RA treatment leads to a statistically significant increase in Fgf9
myocardial proliferation in areas surrounding the inter-transcript levels (**p  0.01), and Epo treatment led to a small but
ventricular groove (Figures 2C and 2D). To quantifymyo-statistically significant decrease in transcript levels (*p  0.05).
cardial proliferation at this location, saggital sections(E–J) Fgf9whole-mount in situ hybridization of E10.5 (E–G) and E12.5
(H–J) hearts. Fgf9 can first be detected in the bulbus (arrowhead) adjacent to the interventricular groove were analyzed.
and lateral regions of the ventricles (arrow) at E10.5 (E and F). Fgf9 Myocardial proliferation was most significantly de-
is prominently detected in the apex of the right ventricle proximal creased at the apex of Fgf9/ hearts (Figures 2C and
to the interventricular groove (arrowhead) and lateral regions of the
2D). The BrdU labeling index decreased from 41.4% inventricle (arrow) at E12.5 (H and I). Frozen sections of E10.5 (G, G)
controls to 25.7% in Fgf9/ ventricles (p .0001) (Figureand E12.5 (J) hearts show that Fgf9 is expressed in the endocardium
2E). No significant changes in cell death were observed(G, J, arrow) at E10.5 and E12.5. Fgf9 is expressed in the epicardium
(G, arrowhead) at E10.5. by both TUNEL labeling and caspase 3 immunohisto-
chemistry (data not shown).
Adjacent saggital sections showed that Fgf9/ heartsfactors. To determine whether RA and/or Epo signaling
had normal cushion morphology and size in addition toregulates Fgf9 expression, we tested the ability of RA
normal patterning of the ventricles into compact andand Epo to induce Fgf9 in organ culture (see below) and
trabecular zones. The compact zone was, however,in cultured primary epicardial cells. FGF9 expression
thinned compared to wild-type controls (Figures 2C andwas measured in cultured cardiac explants by in situ
2D). Finally, the atria were enlarged in Fgf9/ hearts ashybridization and in cultured epicardial cells by qRT-
described previously (Colvin et al., 2001), suggesting anPCR. Interestingly, RA but not Epo treatment upregu-
impairment in cardiac function during embryogenesis.lated FGF9 in both organ culture and cultured primary
Further analysis at E18.5 again revealed normal pat-epicardial cells (Figures 1A–1D). This demonstrates that
terning of the ventricle, septum, valves, and outflow tractFGF9 is an epicardial derived factor that can be regu-
(data not shown).lated by RA signaling.
Histological sections through Fgf9/ newborn heartsTo further investigate the role of FGF9 signaling in
showed atrial enlargement as well as biventricular dila-myocardial development, a detailed analysis of Fgf9 ex-
tion, suggesting that Fgf9/ hearts have a significantpression by in situ hybridization was performed. Whole-
impairment in cardiac function (Figures 2F and 2G).mount staining of E10.5 embryos showed weak but de-
tectable expression in the bulbus (future right ventricle) Fgf9/ newborn mice also have hypoplastic lungs and
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Figure 2. FGF9 Is Required for Myocardial Proliferation
(A and B) Wild-type (A) and Fgf9/ (B) hearts were dissected from
E11.5, E12.5, and E13.5 embryos. Compared to wild-type, Fgf9/ Figure 3. Expression of Fgfrs in the Developing Heart
hearts are smaller and have a disproportionate loss of tissue at the Whole-mount in situ hybridization for Fgfr1 (A), Fgfr2c (B), and
apex of the heart and in regions surrounding the interventricular Fgfr2b (C and D) at E12.5. In situ hybridization was performed on
groove at E12.5 and E13.5. Tracings of Fgf9/ hearts are superim- wild-type (left) and Fgfr1 or Fgfr2 CKO (middle) hearts. Frozen sec-
posed overwild-type hearts to illustrate differences in size. All hearts tions were taken from wild-type hearts (right, 20 magnification).
were photographed at 50 magnification. Fgfr1 and Fgfr2c are expressed in the myocardium (m) and cardiac
(C and D) Sagittal sections through the interventricular groove of cushions (asterisk) while Fgfr2b is expressed in the endocardium
E12.5 wild-type (C) and Fgf9/ (D) embryos. Fgf9/ hearts have a (A–C, right). Fgfr1 and Fgfr2c expression could not be detected in
decreased compact myocardial wall thickness (red bar) and de- Fgfr1mlc2c-cre CKO and Fgfr2mlc2v-cre CKO ventricles, respectively (A, B,
creased number of BrdU-positive myocardial cells at the apex (bot- middle). Fgfr2b expression was present in the ventricles of Fgfr2mlc2v-cre
tom) but not the base (top) of the interventricular groove. 10magni- CKO hearts but could not be detected in the ventricles of Fgfr2 tie1-cre
fication. CKO hearts (C, D, middle). All whole-mount hearts were photo-
(E) Quantification of the percent of BrdU-positive myocardial cells graphed at 50 magnification.
from sagittal sections through the interventricular groove.
(F and G) Sections through wild-type (F) and Fgf9/ (G) newborn
hearts showing marked atrial and ventricular dilation in Fgf9/
hearts.
expression of FGFR1, FGFR2c, and FGFR2b by whole-
mount in situ hybridization. FGFR3 and FGFR4 are not
expressed in the embryonic ventricle (Cool et al., 2002;marked cyanosis (Colvin et al., 2001). Both impaired
cardiac function and cyanosis may potentially contrib- Sugi et al., 2003). Whole-mount staining of E12.5 wild-
type hearts demonstrated that FGFR1, FGFR2c, andute to the atrial and ventricular dilation in Fgf9/ new-
born hearts. FGFR2b were all expressed in the developing heart (Fig-
ures 3A–3D). Sectioning of these hearts revealed that
FGFR1 and FGFR2c were expressed in the myocardiumExpression of FGFRs during Midgestational
Heart Development while FGFR2b was expressed in the endocardium. To
confirm these tissue-specific expression patterns,Four distinct FGFR tyrosine kinases bind and are acti-
vated by most FGFs. Alternative mRNA splicing pro- hearts conditionally lacking either FGFR1 or FGFR2 in
the myocardium (Mlc2v-cre) or endocardium (Tie1-cre)duces FGFRs with unique ligand binding properties.
Splicing tends to be tissue specific, producing epithelial were analyzed (conditional targeting of FGFR1 and
FGFR2 with Mlc2v-cre is described below). Hearts lack-variants (b splice forms) and mesenchymal variants
(c splice forms). FGF9 is capable of activating FGFR1c, ing FGFR1 in the myocardium displayed no expression
of FGFR1 in the ventricles and faint expression in theFGFR2c, FGFR3b, FGFR3c, and FGFR4 in a cell culture
based assay (Ornitz et al., 1996). To identify the targets outflow tract cushion. FGFR2c staining of hearts lacking
FGFR2 in the myocardium also displayed no ventricularof FGF9 signaling in the heart, we characterized the
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expression but did show expression in the outflow tract
cushion. In contrast, FGFR2b staining was similar be-
tween wild-type hearts and hearts lacking FGFR2 in
the myocardium but was absent from the ventricles of
hearts lacking FGFR2 in the endocardium. Sections of
conditional knockout hearts confirmed that FGFR1 and
FGFR2c expression was absent from the myocardium
of hearts lackingmyocardial FGFR1 and FGFR2, respec-
tively (data not shown). Similarly, sections of conditional
knockout hearts lacking FGFR2 in the endocardiumcon-
firmed that FGFR2b expression was absent from the
endocardium (data not shown). From these data, we
conclude that FGFR1 and FGFR2c are expressed in the
myocardium and FGFR2b is expressed in the endo-
cardium.
Conditional Inactivation of FGFRs
in the Myocardium
Since FGFR1 and FGFR2c are expressed in the myocar-
dium and are activated by FGF9 in vitro, we hypothe-
sized that FGFR1 and FGFR2c may be the physiological
receptors for FGF9 during midgestation heart develop-
ment. To test this hypothesis, we conditionally deleted
FGFR1 and FGFR2 in the myocardium using the cre/
loxp system. Conditional alleles for FGFR1 and FGFR2
have been previously generated and characterized (Pir-
vola et al., 2002; Yu et al., 2003). Conditional deletion
was carried out using the Mlc2v-cre transgene, a well-
characterized cre recombinase expressed specifically
in the embryonic ventricle beginning at E10.5 (Chen et
al., 1998).
By crossingmice that are homozygous for conditional
alleles of both FGFR1 and FGFR2 (Fgfr1flox/flox; Fgfr2flox/flox)
with mice carrying one copy of Mlc2v-cre and heterozy- Figure 4. FGF Signaling to the Cardiomyoblast Is Required for Myo-
gous for null alleles of FGFR1 and FGFR2 (Fgfr1/; cardial Development
Fgfr2/; cre/), we were able to produce litters con- (A) Fgfr1, Fgfr2, or both Fgfr1 and Fgfr2 were inactivated in the
myocardium using Mlc2v-cre. Wild-type, Fgfr1CKO, and Fgfr2CKOtaining wild-type, Fgfr1CKO, Fgfr2CKO, and Fgfr1/2DCKO em-
hearts were of similar size. Fgfr1/2 DCKO hearts were severely hypo-bryos. Note that Fgfr1 and Fgfr2 single CKO embryos
plastic. Hearts were dissected from E13.5 embryos (40 magnifi-are also missing one functional allele of FGFR2 and
cation).
FGFR1, respectively. Gross analysis of E13.5 hearts re- (B–E) Sagittal sections through the interventricular groove of wild-
vealed that Fgfr1CKO and Fgfr2CKO hearts were indistin- type (B and D) and Fgfr1/2 DCKO (C and E) embryos.
guishable from wild-type hearts (Figure 4A). The lack of (B and C) H&E-stained sections show that Fgfr1/2 DCKO hearts have
normal patterning of the ventricle and cardiac cushions but displayphenotype in Fgfr1CKO hearts was initially unexpected,
enlarged atrial appendages and fail to fill the pericardial cavity (as-given that FGFR1 was thought to be the only FGFR
terisk); 4 magnification.expressed in the myocardium (Pennisi et al., 2003). This
(D and E) Fgfr1/2 DCKO hearts have a decreased number of BrdU-
is, however, explained by the aforementioned data dem- positive myocardial cells throughout both the apex and base of the
onstrating FGFR2c expression in the myocardium. ventricle compared to wild-type hearts, 10 magnification.
In contrast toFgfr1CKO andFgfr2CKOhearts, hearts lacking (F) Quantification of the percent of BrdU-positive myocardial cells
from sagittal sections through the interventricular groove.both FGFR1 and FGFR2 in the myocardium (Fgfr1/2DCKO)
(G andH) Sections throughwild-type (G) andFgfr1/2 DCKO (H) newbornwere severely hypoplastic (Figure 4A). Histological sec-
hearts showing ventricular dilation in Fgfr1/2 DCKO hearts.tions of Fgfr1/2DCKO hearts demonstrated that, like
Fgf9/ hearts, patterning of the cardiac cushions, sep-
tum, and ventricular layers appeared normal (data not
shown). Saggital sections through E12.5 embryos
The BrdU labeling index was reduced from 40.9% inshowed that Fgfr1/2DCKO hearts were unable to fill the
wild-type to 20.2% in Fgfr1/2DCKO ventricles (p  .0001;pericardial space and displayed enlarged atria and thin-
Figure 4F). No increase in cell death was detected byning of the ventricular wall (Figures 4B and 4C). BrdU
TUNEL labeling and caspase3 immunohistochemistrystaining of adjacent sections indicated that, like Fgf9/
(data not shown). From these data, we conclude thathearts, myocardial proliferation was reduced (Figures
there exists a functional requirement for both FGFR14D and 4E). However, unlike Fgf9/ hearts, myocardial
and FGFR2 in the developing myocardium and that FGFproliferation was decreased throughout the base and
signaling is an essential regulator of myocardial prolifer-apex of both ventricles, suggesting that additional FGF
ligands may function during myocardial development. ation.
FGF Regulation of Myocardial Growth
89
Figure 5. FGF Signaling to the Cardiomyo-
blast Regulates the Progression of Myocar-
dial Differentiation
(A–C) Fgfr1/2DCKO hearts have normal expres-
sion of early cardiac markers. Whole-mount
in situ hybridization for (A) Nkx2.5, (B) Anf,
and (C) -Mhc at E12.5. 40 magnification.
(D–F) Fgf9/ and Fgfr1/2DCKO hearts have in-
creased amounts of sarcomeric actin com-
pared to wild-type hearts.
(D and E) Immunohistochemical staining for
sarcomeric actin in wild-type and Fgf9/
hearts. Fgf9/ hearts show increased inten-
sity and area of staining within the boxed re-
gions, 4 magnification.
(E) 20magnification of boxed regions in (D).
(F) Fgfr1/2DCKO hearts show increased inten-
sity and area of staining throughout the ven-
tricular myocardium, 20 magnification.
(G–J) Electron microscopy of wild-type (G
and I) and Fgfr1/2DCKO (H and J) hearts. Fgfr1/
2DCKO hearts have thicker actin bundles (sar-
comeres) (red bars) compared to wild-type
hearts. (G and H) 10,000 magnification; (I
and J) 33,000 magnification.
(K) Quantification of sarcomere thickness
demonstrated that Fgfr1/2DCKO sarcomeres
are 1.6 times thicker than wild-type sarco-
meres (**p  0.0001).
Even though myocardial proliferation was dramati- was equivalent between wild-type and Fgfr1/2DCKO
hearts, indicating that the acquisition of the cardiac fatecally reduced in Fgfr1/2DCKO hearts, some cardiomy-
oblasts continued to proliferate. One possible explana- (specification of atria, left ventricle, and right ventricle)
is not dependent on myocardial FGF signaling after em-tion is that other receptor tyrosine kinase (RTK) systems
may function redundantly with FGF signaling in the de- bryonic day 10.5. These data are consistent with known
roles for FGF signaling in cardiogenesis prior to E10.5veloping myocardium. Consistent with this, ErbB-2
(EGF) and PDGFR	 knockout mice also have hypoplas- and the timing of Mlc2v-cre expression.
Despite unaltered expression of several cardiacmark-tic hearts and reduced myocardial proliferation (Chan
et al., 2002; Price et al., 2001). ers, histological examination of wild-type, Fgf9/, and
Fgfr1/2DCKO hearts revealed that individual cardiomy-Similar to Fgf9/ newborn hearts, histological sec-
tions through Fgfr1/2DCKO newborn hearts showed biven- oblasts appeared larger in Fgf9/ and Fgfr1/2DCKO hearts
(data not shown). Since cardiomyoblasts enlarge andtricular dilation (Figures 4G and 4H). This indicates that
FGFR1 and FGFR2 activity in the developing myocar- accumulate increasing amounts of cardiac actin as they
fully differentiate (Carrier et al., 1992; Sugi and Lough,dium is essential for normal cardiac function. Moreover,
this suggests that atrial and ventricular dilation in FGF9 1992), we postulated that Fgf9/ and Fgfr1/2DCKO hearts
may undergo premature differentiation. Consistent withnewborn hearts is, at least in part, due to loss of cardiac
FGF9 signaling. this, both Fgf9/ and Fgfr1/2DCKO hearts showed alter-
ations in the expression of sarcomeric actin. Immunohis-In addition tomitogenesis, FGFsignals have also been
implicated in regulating the acquisition and mainte- tochemical staining for sarcomeric actin inFgf9/hearts
showed increased staining area and intensity in themyo-nance of the cardiac fate (cardiogenesis) (Solloway and
Harvey, 2003). To testwhether this process is dependent cardium in regions corresponding to those where prolif-
eration was decreased (Figures 5D and 5E). Fgfr1/2DCKOon FGFR signaling during midgestation heart develop-
ment, we examined several markers of cardiac differen- hearts displayed increased staining area and intensity
throughout the myocardium (Figure 5F). To confirmtiation. The expression of Nkx2.5 (pan cardiac marker),
-Mhc (ventricular marker), and Anf (left ventricle
right these observations, wild-type and Fgfr1/2DCKO were ana-
lyzed by transmission electron microscopy. Direct visu-ventricle) were analyzed by whole-mount in situ hybrid-
ization in E12.0–E13.0 wild-type and Fgfr1/2DCKO hearts alization of cardiac actin bundles revealed that the thick-
ness of each band of cardiac actin was increased in the(Figures 5A–5C). The expression of all three markers
Developmental Cell
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Figure 6. FGF9 Signals to the Myocardium
through FGFR1c and FGFR2c
(A–C) BrdU staining of sections from hearts
cultured for 24 hr with BSA- or FGF9-soaked
beads. The position of the bead is denoted
by the gray circle. Compared to BSA-treated
hearts (A), FGF9 beads were able to induce
a localized increase inmyocardial BrdU stain-
ing in wild-type (B) but not Fgfr1/2 DCKO hearts
(C). 20 magnification.
(D–F) BrdU-stained sections of hearts cul-
tured for 24 hr with either BSA- (D), FGF2- (E),
or FGF10- (F) soaked heparin beads placed in
the septal groove. FGF2-soaked beads in-
duced a localized increase in BrdU staining
proximal to the bead, whereas BSA- and
FGF10-soaked beads elicited no response.
20 magnification.
(G) Quantification of the percent of BrdU-pos-
itive nuclei showed that wild-type but not
Fgfr1/2 DCKO hearts treated with FGF9-soaked
beads showed a significant increase in the
percent of BrdU-positive nuclei proximal to
the bead (**p  0.001). Fgfr1/2 DCKO hearts
showed a small but significant decrease in
the percent of BrdU-positive nuclei com-
pared to BSA-treated hearts (**p  0.001).
(H) Quantification of the percent of BrdU-pos-
itive nuclei showed that only FGF2-soaked
beads significantly increased the percent of
BrdU-positive nuclei proximal to the bead
(**p  0.0001).
myocardiumofFgfr1/2DCKO hearts compared towild-type to promote proliferation in wild-type, Fgfr1CKO, Fgfr2CKO,
and Fgfr1/2DCKO heart explants was tested. Consistentlittermates (Figures 5G–5J). Quantification of sarcomere
with the expression of both FGFR1 and FGFR2 in thethickness demonstrated thatFgfr1/2DCKO sarcomeres av-
myocardium and the lack of an obvious hypoplasticeraged 1.01 m in thickness compared to 0.65 m in
phenotype in Fgfr1CKO and Fgfr2CKO hearts, FGF9 beadswild-type hearts (p  0.0001; Figure 5K).
were able to induce equivalent levels of proliferation
in Fgfr1CKO, Fgfr2CKO, and wild-type hearts (data not
FGF9 Signals through FGFR1c and FGFR2c shown). In contrast, FGF9 beads were unable to induce
in the Myocardium proliferation in Fgfr1/2DCKO hearts (Figures 6A–6C, 6G).
The experiments presented demonstrate that FGF9 and Quantification of BrdU incorporation demonstrated that
myocardial FGFR signaling are required to regulate cell BSA-treated hearts had aBrdU labeling of 13.6%, FGF9-
proliferation anddifferentiationof establishedcardiomy- treated wild-type hearts had an index of 26.8%, and
oblasts. TodeterminewhetherFGFsignaling is sufficient FGF9-treated Fgfr1/2DCKO hearts had an index of 11.1%.
to mediate cardiomyoblast proliferation and to rigor- FGF9-treated wild-type hearts showed a statistically sig-
ously define the relationship between FGF9, FGFR1, and nificant increase in BrdU labeling index (p 0.001) com-
FGFR2 in the developing ventricle, we developed an pared to BSA-treated hearts. FGF9-treated Fgfr1/2DCKO
organ explant culture system. hearts had a statistically significant decrease in BrdU
In the literature, there are few examples of midgesta- labeling index (p  0.0001) compared to BSA-treated
tion heart explant cultures (Chen et al., 2004; Zhao and hearts, suggesting that our heart cultures contain some
Rivkees, 2000). We have found that E10.5–E11.5 hearts endogenous myocardial FGF signaling.
can be cultured on a micropore filter for at least 72 hr. Since FGFR1 and FGFR2c are expressed in the myo-
To test the feasibility of this system, either BSA- or cardium and FGFR2b is expressed in the endocardium,
FGF9-soaked heparin beads were placed in the septal we postulated that FGF9 signals to the myocardium
groove and hearts were then cultured for 24, 48, or 72 through c splice forms of FGFRs. Consistent with this,
hr. Beginning after 48 hr, a substantial increase in tissue FGF2 beads (a known activator FGFR1c, FGFR2c,
mass was observed around the FGF9 bead compared FGFR3c, and FGFR4) were able to induce proliferation,
to the BSA bead. Moreover, by 72 hr the septal groove while FGF10 beads (a specific activator of FGFR1b and
of FGF9-treated hearts was filled in by tissue (data not FGFR2b) (Ornitz and Itoh, 2001) were not able to induce
shown). BrdU labeling of hearts cultured for 24 hr proliferation in this system (Figures 6D–6F and 6H).
showed that FGF9 beads were able to induce a robust Quantification of BrdU incorporation demonstrated that
localized increase in proliferation compared to BSA BSA-treated hearts had a BrdU labeling index of 14.3%,
beads (Figures 6A and 6B). FGF2 had an index of 25.6%, and FGF10 had an index of
To establish that FGF9 signals to the myocardium 13.2%. Only FGF2-treated hearts showed a statistically
significant increase in BrdU incorporation (p  .00001)through FGFR1 and FGFR2, the ability of FGF9 beads
FGF Regulation of Myocardial Growth
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Figure 7. Redundancy of FGF Ligands in the
Developing Heart
(A–D) Fgfr1/2DCKO hearts display a greater de-
gree of hypoplasia than do Fgf9/ hearts at
E13.5. 40 magnification.
(E–J) Compared to Fgf9, Fgf16 and Fgf20 are
expressed in overlapping and distinct regions
of the embryonic heart. Whole-mount in situ
hybridization for Fgf16 (E–G) and Fgf20 (H–J)
in E10.5 and E12.5 hearts. Expression pat-
terns are enclosed by the dashed lines (F and
I). The arrowhead represents the region
where FGF9expression does not overlapwith
Fgf16 and Fgf20 expression. 50 magnifi-
cation.
(E and H) Fgf16 and Fgf20 are expressed in
the epicardium and endocardium of E10.5
hearts. 10magnification, insets 30magni-
fication.
(G and J) Frozen sections of (F) and (I) show-
ing that Fgf16 and Fgf20 are expressed in the
endocardium at E12.5. 10 magnification.
compared to BSA-treated hearts. From these data, we the loss of FGF9 activity. Sectioning of these tissues
showed that like FGF9, FGF16 and FGF20 were ex-conclude that FGF9 activity ismediated through FGFRc-
splice forms. pressed in the endocardium at E10.5 and E12.5 (Figures
7E, 7G, 7H, and 7J). Importantly, Fgf9, Fgf16, and Fgf20These data indicate that (1) a single FGFR allele is
sufficient to mediate a FGF9 signal, and (2) FGF9 signals expressionwasalso observed in the epicardiumofE10.5
embryos (Figures 1G, 7E, and 7H).to the myocardium through both FGFR1c and FGFR2c.
Furthermore, even though FGF9 is also able to activate It is well established that FGF ligands belonging to
the same subgroup share biochemical properties (OrnitzFGFR3c, FGFR3b, and FGFR4, we can conclude that
FGFR1c and FGFR2c are the only FGFRs functionally and Itoh, 2001). To confirm that this relationship holds
true in the FGF9/16/20 subgroup, we examined receptorrequired in the developing myocardium at this stage
of development. specificity using the BaF3 assay (Ornitz et al., 1996). Like
FGF9, FGF16 and FGF20 activated FGFR1c, FGFR2c,
FGFR3b, FGFR3c, and FGFR4 in this assay (FiguresIdentification of Additional FGF Ligands
in the Developing Heart 8A and 8B). Furthermore, FGF16- and FGF20-soaked
heparin beads were both able to promote myocardialAs noted above, Fgfr1/2DCKO hearts have a significantly
more severe and uniform hypoplasia than Fgf9/ hearts proliferation in cultured E10.5 hearts (Figures 8C, 8D,
and 8F). Quantification of BrdU incorporation demon-(Figures 7A–7D), suggesting that additional FGF ligands
must regulatemyocardial development alongwith FGF9. strated that FGF16- and FGF20-treated wild-type hearts
had a statistically significant increase in BrdU labelingOne potential candidate is FGF2, given that it is a known
cardiac mitogen and is expressed in the developing index (25.2%, p  0.0001 and 27.2%, p  0.0001) com-
pared to wild-type hearts (13.6%) (Figure 8H). Moreover,heart. To address this possibility, we generated Fgf2/
Fgf9 double knockout (DKO) mice. Fgf2/Fgf9 DKOmice FGF16- and FGF20-soaked heparin beads were unable
to induce myocardial proliferation in Fgfr1/2DCKO heartswere indistinguishable from Fgf9/ and Fgf9/; Fgf2/
littermates at E13.5 and E18.5 (data not shown). (Figures 8C, 8E, and 8G). The BrdU labeling index for
FGF16-treated Fgfr1/2DCKO hearts was 12.0% andOther potential candidates include FGF16 and FGF20,
FGFs that, along with FGF9, form an evolutionarily con- FGF20-treated Fgfr1/2DCKO hearts was 10.9%. Both
FGF16- and FGF20-treated Fgfr1/2DCKO hearts had a sta-served subgroup within the FGF family (Ornitz and Itoh,
2001; Itoh andOrnitz, 2004). In situ hybridization analysis tistically significant decrease in BrdU incorporation
compared to wild-type hearts (p  .05 and p  0.01,of E12.5 hearts demonstrated that Fgf16 and Fgf20were
also expressed in the embryonic ventricle. Comparison respectively) (Figure 8H). These data suggest that FGF16
and FGF20 may function redundantly with FGF9 in thewith Fgf9 expression patterns showed that Fgf16 and
Fgf20 are expressed in both overlapping and unique developing heart and, like FGF9, signal through FGFR1c
and FGFR2c in the myocardium.ventricular domains. Fgf16 expression localized to the
base of the left ventricle and the outflow tract (Figures
7E–7G). Fgf20 expressionwas detected in the left ventri- Discussion
cle overlapping and extending apical to that of Fgf16
(Figures 7H–7J). In addition, FGF20 was expressed in FGF Signaling and Control of Myocardial
Proliferationthe outflow tract and throughout the right ventricle, ex-
cluding the most apical region. It is important to note Recently, several groups have postulated that epicardial
derived signals regulate myocardial proliferation in thethat Fgf9 and not Fgf16 or Fgf20 is expressed at the
apex of the right ventricle, the region most affected by midgestation heart (Chen et al., 1998; Kwee et al., 1995;
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Figure 8. FGF16 and FGF20 Possess Identi-
cal Activity and Receptor Specificity to FGF9
(A and B) FGF16 (A) and FGF20 (B) can acti-
vate FGFR1c, 2c, 3c, 3b, and 4 but not
FGFR1b or 2b in BaF3 cells in vitro. Data
shown as mean of three assays.
(C–G) BrdU staining of hearts cultured for 24
hr with BSA-, FGF16-, or FGF20-soaked hep-
arin beads. The position of the bead is de-
noted by the gray circle. Similar to FGF9-
soaked beads, FGF16- and FGF20-soaked
beads increased BrdU incorporation proxi-
mal to the bead in wild-type hearts (D and F)
compared toBSA-treated controls (C). FGF16
and FGF20 were unable to increase BrdU in-
corporation in Fgfr1/2 DCKO hearts (E and G).
20 magnification.
(H) Quantification of the percent of BrdU-pos-
itive nuclei showed that FGF16- and FGF20-
soaked beads significantly increased the per-
cent of BrdU-positive nuclei in wild-type
hearts (***p  0.0001). Fgfr1/2 DCKO hearts
treated with FGF16- and FGF20-soaked
beads showed a small but statistically signifi-
cant decrease in the percent of BrdU-positive
nuclei (*p  0.05, **p  0.01).
(I) Model showing epicardial and endocardial
sources of FGF9, 16, and 20 signaling to
FGFR1c and FGFR2c in the myocardium. En,
endocardium;M,myocardium; Ep, epicardium.
Mic et al., 2002; Moore et al., 1999; Pennisi et al., 2003; not dependent on FGFR signaling during the second
week of embryogenesis. An alternative explanation isWu et al., 1999; Yang et al., 1995). Here, we provide
functional evidence that FGF9, and presumably FGF16 that FGFR1 is not the only functional FGFR in cardiomy-
oblasts during the secondweek of embryogenesis. Con-andFGF20, constitute anendocardial/epicardial derived
signal that regulates myocardial proliferation and differ- sistent with this, we show that in the mouse, FGFR2c
is expressed in themyocardium and is required togetherentiation (Figure 8I). Furthermore, we show that FGF9,
FGF16, and FGF20 signal to themyocardiumspecifically with FGFR1 to mediate cardiomyoblast proliferation at
a stage equivalent to the second week of gestation inthrough FGFR1c and FGFR2c. The data presented here
(1) identifies FGFs as a candidate for the presumptive the chick.
FGF2 is prominently expressed in the myocardiumepicardial derived signal, (2) defines FGFs as an unrec-
ognized endocardial derived signal, and (3) offers a solu- (Detillieux et al., 2003; Pennisi et al., 2003). However, to
date no functional requirement for FGF2 in heart devel-tion to the disparity between the potent effects of FGFs
on cardiomyoblasts in culture and the lack of cardiac opment has been uncovered (Detillieux et al., 2003). We
were initially surprised that removal of FGF2 had nophenotypes in other FGF knockout mice. Finally, we
have uncovered unexpected redundancy between effect on Fgf9/ embryonic hearts. Possible explana-
tions for this include: (1) FGF2 cannot efficiently activateFGFR1 and FGFR2 in the myocardium.
In contrast to the evidence presented here, prior stud- myocardial FGFRs in vivo; (2) FGF16 andFGF20 function
redundantly with FGF2; and (3) FGF9 is required fories in the chick have argued that FGFR signaling does
not regulate cardiomyoblast proliferation after the loop- FGF2 signaling. Previous work indicating that FGF2-
soaked beads are able to induce myocardial prolifera-ing stage. FGFR1 dominant-negative (DN) and antisense
constructs injected into embryonic day 3 hearts sup- tion in the chick suggests that the myocardium can
respond to FGF2 (Franciosi et al., 2000). Although it ispressed cardiac myocyte proliferation during the first
week of embryogenesis (cardiac looping) but had no possible that the chick and mouse may respond differ-
ently to FGF2, we believe this is not the case, sinceeffect during the second week of embryogenesis (post
looping) (Mima et al., 1995). From these data, the authors mouse hearts can respond to FGF2 in our organ cul-
ture model.concluded that FGFR1 was themajor FGFR during heart
development and that cardiomyoblast proliferation was We favor the latter two explanations. If FGF2 functions
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redundantly with FGF16 and FGF20, then we would ex- explants and cultured epicardial cells. Moreover, RA
pect that removal of FGF16 and FGF20 would uncover signaling is known to control FGF expression in other
a requirement for FGF2 in the developing heart. Alterna- systems (Gaetano et al., 2001; Murakami et al., 1999).
tively, it is possible that FGF9, FGF16, and FGF20 are
required for FGF2 signaling. If this were true, deletion FGF Signaling Regulates the Progression
of FGF9 would result in the concurrent loss of FGF2 of Myocardial Differentiation
signaling in the affected areas. This is consistent with
FGF signals are known to promote the acquisition of
previous work demonstrating that removal of the epicar-
the cardiac fate (cardiogenesis). Since cardiogenesis
dium in the chick results in decreased myocardial prolif-
occurs well before the activation of MLC2v-cre expres-
eration and FGF2 expression (Pennisi et al., 2003).
sion (E10.5), the unaltered expression of Nkx2.5, Anf,
and-Mhc inFgfr1/2DCKO heartswasnot surprising.How-
FGF9 as a Retinoic Acid Inducible Factor
ever, the increased cell size and increased amounts of
RA and Epo signaling are known to regulate unidentified
sarcomeric actin in Fgf9/ and Fgfr1/2DCKO hearts wasepicardial-derived mitogens that act on cardiomy-
unexpected. Given the observation that cardiomyo-oblasts. Interestingly, RA and Epo are thought to induce
blasts accumulate increasing amounts of cardiac (sar-distinct epicardial derived factors (Stuckmann et al.,
comeric) actin as they differentiate, this finding suggests2003). Consistent with this model, we demonstrate that
that FGF signaling functions to delay cardiomyoblastFGF9 expression is upregulated by RA but not Epo.
differentiation. We therefore postulate that FGF signal-These data suggest that FGF9 and possibly other FGFs
ing in the developing myocardium functions to spatially(i.e., FGF16 andFGF20)may constitute theRA-regulated
and temporally coordinate cardiomyoblast proliferationepicardial derived mitogen.
with differentiation.Similar to Fgf9/ and Fgfr1/2DCKO hearts, RXR	 and
RALDH2 knockout hearts display profound myocardial
Experimental Procedureshypoplasia, albeit significantly more severe (Mic et al.,
2002; Sucov et al., 1994). The greater extent of hypopla-
Epicardial Cell Culture
sia seen in RXR	 and RAR knockouts compared to Embryonic day 10.5–11.5 hearts were aseptically dissected, and
Fgfr1/2DCKO hearts is likely a result of the timing of FGFR1 the atria, outflow tract, and cardiac cushions were removed. The
and FGFR2 deletion in the myocardium. That is, RA remaining ventricular tissue was cut into four pieces, added to 2 ml
of media (DMEM/10% FCS), and cultured for 3–4 days. The myocar-induces FGFs in the epicardium prior to deletion of
dial tissue was then removed and the remaining halo cells culturedFGFR1 and FGFR2 by Mlc2v-cre (E10.5). Alternatively,
for 2 weeks (Chen et al., 2002). At this time RA (10 M), Epo (2 units/it is possible that RA induces, in addition to FGFs, other
ml), or DMSO was added. After 48 hr, RNA was isolated using the
epicardial derived mitogens. Qiagen RNA miniprep system.
We have shown that RA signaling is sufficient to in-
duce FGF9 expression in epicardial cells. To determine
Embryonic Heart Organ Culture
whether RA signaling is required for FGF9 expression Embryonic day 10.5–11.5 hearts were dissected under aseptic con-
in the epicardium and/or endocardium, we examined ditions and placed on a Transwell filter over wells containing 2 ml
RXR	 knockouts. Unexpectedly, RXR	/ hearts had in- of media (DMEM/10% FCS). After incubating for 1 hr (37C/5%CO2),
protein-soaked heparin beads were placed in the septal groovecreased Fgf9 expression in the epicardium at E11.5.
and the explants cultured for up to 72 hr at 37C/5% CO2. HeartSeveral possibilities accounting for the increased Fgf9
morphology was preserved for at least 72 hr in culture. Histologicalexpression in RXR	/ hearts exist. One explanation is
and immunohistochemical (sarcomeric actin and PECAM) analysisthat Fgf9 expression, in addition to RA signaling, is regu-
of organ culture sections demonstrated that cardiomyoblasts made
lated by a feedback loop. RXR	/ mice display signifi- up the majority of tissue while endocardial and cardiac cushion
cant ventricular thinning and dilation by E11.5. The pres- tissue made up the minority of cells. Organ cultures were harvested
ence of such a severe phenotype is likely to activate at 24 hr. The hearts were removed from the filters and fixed. The
bead was removed prior to photography and sectioning.compensatory pathways that promote cardiomyoblast
Protein was loaded onto heparin-coated acrylic beads (Sigma).proliferation. Thus, the increased Fgf9 expression pres-
Beads were washed three times in PBS and incubated with eitherent in RXR	/ hearts may be a result of triggering such
0.1% BSA or 100 ng/l FGFs (2, 9, 10, 16, 20) (Peprotech) for 30a compensatory pathway. Alternatively, it is possible
min at 37C. Retinoic acid (Sigma) was used at a final concentration
that deletion of RXR	 disrupts multiple signaling path- of 10 M. Epo was used at a final concentration of 2 units/ml.
ways that control Fgf9 expression. RXRs are corecep-
tors for molecules other than the RA receptor (RAR). qRT-PCR Analysis
These include the peroxisome proliferator-activated re- qRT-PCR analysis of Fgf9 expression was performed using SYBR
ceptors (PPAR), the vitamin D receptor (VDR), the liver green (applied biosystems) and a BioRad iCycler. Fgf9 primers were
X receptor (LXR), the thyroid hormone receptor (TR), and developed and optimized. Forward primer (exon 1), 5-ACTATC
CAGGGAACCAGGAAAGA; reverse primer (exon 2), 5-CTCGTTCATinsulin-like growth factorbindingprotein3 (IGFBP-3) (Apri-
GCCGAGGTAGAGT. Data shown as mean SD, n 5 independentletti et al., 1998; Cabrero et al., 2002; Carlberg and
pcr reactions from two pooled RNA samples under each condition.Saurat, 1996; Edwards et al., 2002; Lee and Cohen,
2002). Affected pathways may both positively and nega-
Whole-Mount In Situ Hybridizationtively regulate Fgf9 expression, the sum of which leads
Whole-mount in situ hybridization was performed as previously de-to increased Fgf9 expression. Examining Fgf9 expres-
scribed (Wilkinson, 1992). Tissues were photographed and then
sion in Raldh2 knockout mice would address this issue. cryo-sectioned (10 m), mounted on slides, and rephotographed.
Finally, it is possible that RA signaling is not required In situ probes used were Nkx2.5 (Chen et al., 1994), Anf (Zeller et
for Fgf9 expression in vivo. We believe that this is un- al., 1987), -Mhc (Boheler et al., 1992), Fgf9 (Colvin et al., 1999),
Fgf16 (Miyake et al., 1998), and Fgf20 (Hajihosseini and Heath, 2002).likely given that RA upregulated Fgf9 expression in heart
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Immunohistochemistry heavy chains and sarcomeric alpha-actins are regulated through
transcriptional mechanisms. Results from nuclear run-on assays inParaffin sections (4 m) were dewaxed, rehydrated, incubated in
methanol/hydrogen peroxide, antigen unmasked, and blocked in isolated rat cardiac nuclei. J. Biol. Chem. 267, 12979–12985.
10% goat serum. Antigen unmasking was performed by incubating Cabrero, A., Laguna, J.C., and Vazquez, M. (2002). Peroxisome pro-
sections in 0.1% trypsin for 10 min at 37C. Primary antibodies liferator-activated receptors and the control of inflammation. Curr.
used were BrdU (mouse IgG, Becton and Dickinson, 1:100) and Drug Targets Inflamm. Allergy 1, 243–248.
sarcomeric actin (mouse IgM, Sigma, 1:400). Biotinylated goat anti-
Carlberg, C., and Saurat, J.H. (1996). Vitamin D-retinoid association:
mouse IgG or anti-mouse IgM were used, followed by Vectastain
molecular basis and clinical applications. J. Investig. Dermatol.
ABC-peroxidase reagent and DAB visualization (Vector).
Symp. Proc. 1, 82–86.
Carrier, L., Boheler, K.R., Chassagne, C., de la Bastie, D., Wisnew-Proliferation Analysis
sky, C., Lakatta, E.G., and Schwartz, K. (1992). Expression of theFor embryos, time-mated females were injected IP with BrdU (100
sarcomeric actin isogenes in the rat heart with development andg/g body weight) 1 hr prior to sacrifice. BrdU immunohistochemis-
senescence. Circ. Res. 70, 999–1005.try on sections was performed as described (Naski et al., 1998).
Chan, R., Hardy, W.R., Laing, M.A., Hardy, S.E., and Muller, W.J.Sections were counterstained with hematoxylin. For statistical anal-
(2002). The catalytic activity of the ErbB-2 receptor tyrosine kinase isysis, nine sections were analyzed, three sections from three different
essential for embryonic development. Mol. Cell. Biol. 22, 1073–1078.specimens. The number of BrdU-positive nuclei relative to the total
number of nuclei was counted from two 40 fields per section. Data Chen, Z., Friedrich, G.A., and Soriano, P. (1994). Transcriptional
shown as mean  SD. enhancer factor 1 disruption by a retroviral gene trap leads to heart
For organ cultures, 30g/ml BrdU was added to the culturemedia defects and embryonic lethality in mice. Genes Dev. 8, 2293–2301.
1 hr prior to fixation. BrdU incorporation was detected by immuno- Chen, J., Kubalak, S.W., and Chien, K.R. (1998). Ventricular muscle-
histochemistry. After fixation, tissueswere dehydrated in amethanol restricted targeting of the RXRalpha gene reveals a non-cell-autono-
series, incubated in methanol/hydrogen peroxide, rehydrated, incu- mous requirement in cardiac chamber morphogenesis. Develop-
bated in 2N hydrochloric acid, and blocked in PBSST (5% goat ment 125, 1943–1949.
serum/PBS 0.1%Triton X100). Primary antibody usedwas goat anti-
Chen, T.H., Chang, T.C., Kang, J.O., Choudhary, B., Makita, T., Tran,mouse BrdU (Becton and Dickinson, 1:100). Biotinylated goat anti-
C.M., Burch, J.B., Eid, H., and Sucov, H.M. (2002). Epicardial induc-mouse IgG (Vector, 1:200) was used followed by Vectastain ABC-
tion of fetal cardiomyocyte proliferation via a retinoic acid-inducibleperoxidase reagent and DAB visualization (Vector). All antibody and
trophic factor. Dev. Biol. 250, 198–207.ABC reagent dilutions were done in PBSST. Antibody and ABC
Chen, H., Shi, S., Acosta, L., Li, W., Lu, J., Bao, S., Chen, Z., Yang,reagent incubations were carried out at 4C overnight. Following
Z., Schneider, M.D., Chien, K.R., et al. (2004). BMP10 is essentialeach overnight incubation, tissues were washed five times (1 hr
for maintaining cardiac growth during murine cardiogenesis. Devel-each at 4C) with PBSST.
opment 131, 2219–2231.
Transmission Electron Microscopy Colvin, J.S., Feldman, B., Nadeau, J.H., Goldfarb, M., and Ornitz,
Tissues were fixed in 2.5% PFA/2% GAD for 1 hr at 4C, incubated D.M. (1999). Genomic organization and embryonic expression of the
in 1% osmium tetraoxide for 1 hr at 25C, and stained in 1% uranyl mouse fibroblast growth factor 9 gene. Dev. Dyn. 216, 72–88.
acetate. Following staining, tissues were dehydrated in a progres- Colvin, J.S., White, A., Pratt, S.J., and Ornitz, D.M. (2001). Lung
sive series of ethanol and propylene oxide and embedded in Epon hypoplasia and neonatal death in Fgf9-null mice identify this gene
(Electron Microscopy Sciences). Blocks were sectioned at 70 nm as an essential regulator of lung mesenchyme. Development 128,
in a RMC Ultra microtome with a Delaware diamond knife and 2095–2106.
poststained in Reynolds lead and uranyl acetate. Sections were
Cool, S.M., Sayer, R.E., van Heumen, W.R., Pickles, J.O., and Nur-viewed with a JEOL 100C transmission electron microscope.
combe, V. (2002). Temporal and spatial expression of fibroblastFor quantification of sarcomere thickness, two wild-type and
growth factor receptor 4 isoforms in murine tissues. Histochem. J.DCKO specimens were analyzed. The thickness of five sarcomere
34, 291–297.bundles located in the compact layer weremeasured for each speci-
Detillieux, K.A., Sheikh, F., Kardami, E., and Cattini, P.A. (2003).men. Data shown as mean  SD, n  10.
Biological activities of fibroblast growth factor-2 in the adultmyocar-
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